NO951608L - Anvendelse av BHAP-forbindelser i kombinasjon med andre ikke-nukleoside reverstranskriptaseinhibitorer for behandling av HIV-infeksjon - Google Patents

Anvendelse av BHAP-forbindelser i kombinasjon med andre ikke-nukleoside reverstranskriptaseinhibitorer for behandling av HIV-infeksjon

Info

Publication number
NO951608L
NO951608L NO951608A NO951608A NO951608L NO 951608 L NO951608 L NO 951608L NO 951608 A NO951608 A NO 951608A NO 951608 A NO951608 A NO 951608A NO 951608 L NO951608 L NO 951608L
Authority
NO
Norway
Prior art keywords
hiv
treatment
bhap
compounds
combination
Prior art date
Application number
NO951608A
Other languages
English (en)
Norwegian (no)
Other versions
NO951608D0 (no
Inventor
William Gary Tarpley
Thomas Jerome Dueweke
Donald Herman M D Batts
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of NO951608D0 publication Critical patent/NO951608D0/no
Publication of NO951608L publication Critical patent/NO951608L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO951608A 1992-10-28 1995-04-27 Anvendelse av BHAP-forbindelser i kombinasjon med andre ikke-nukleoside reverstranskriptaseinhibitorer for behandling av HIV-infeksjon NO951608L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96763992A 1992-10-28 1992-10-28
US1711993A 1993-02-12 1993-02-12
PCT/US1993/008354 WO1994009781A1 (en) 1992-10-28 1993-09-10 Use of bhap compounds in combination with other non-nucleoside reverse transcriptase inhibitors for the treatment of hiv infection

Publications (2)

Publication Number Publication Date
NO951608D0 NO951608D0 (no) 1995-04-27
NO951608L true NO951608L (no) 1995-06-28

Family

ID=26689480

Family Applications (1)

Application Number Title Priority Date Filing Date
NO951608A NO951608L (no) 1992-10-28 1995-04-27 Anvendelse av BHAP-forbindelser i kombinasjon med andre ikke-nukleoside reverstranskriptaseinhibitorer for behandling av HIV-infeksjon

Country Status (12)

Country Link
EP (1) EP0666744A1 (fi)
JP (1) JPH08502745A (fi)
KR (1) KR950703958A (fi)
AU (1) AU4848293A (fi)
CA (1) CA2145545A1 (fi)
CZ (1) CZ69695A3 (fi)
FI (1) FI952018A (fi)
HU (1) HUT72050A (fi)
MX (1) MX9306031A (fi)
NO (1) NO951608L (fi)
PL (1) PL308551A1 (fi)
WO (1) WO1994009781A1 (fi)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW406075B (en) * 1994-12-13 2000-09-21 Upjohn Co Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds
WO2002072548A2 (en) 2001-03-09 2002-09-19 Ortho-Mcneil Pharmaceutical, Inc. Heterocyclic compounds and their use as histamine h4 ligands.
WO2004022060A2 (en) 2002-09-06 2004-03-18 Janssen Pharmaceutica, N.V. (1h-benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine h4-receptor antagonists for the treatment of inflammatory and allergic disorders
TW201201813A (en) 2010-03-31 2012-01-16 Arqule Inc Substituted benzo-pyrido-triazolo-diazepine compounds
US8569331B2 (en) 2010-11-01 2013-10-29 Arqule, Inc. Substituted benzo[f]lmidazo[1,2-d]pyrido[2,3-b][1,4]diazepine compounds

Also Published As

Publication number Publication date
EP0666744A1 (en) 1995-08-16
CZ69695A3 (en) 1995-12-13
WO1994009781A1 (en) 1994-05-11
MX9306031A (es) 1994-04-29
PL308551A1 (en) 1995-08-21
FI952018A0 (fi) 1995-04-27
FI952018A (fi) 1995-04-27
CA2145545A1 (en) 1994-05-11
KR950703958A (ko) 1995-11-17
AU4848293A (en) 1994-05-24
JPH08502745A (ja) 1996-03-26
NO951608D0 (no) 1995-04-27
HUT72050A (en) 1996-03-28
HU9501218D0 (en) 1995-06-28

Similar Documents

Publication Publication Date Title
DE69129800T2 (de) Behandlung von menschlichen retrovirus-infektionen mit 2',3'-dideoxyinosin
ATE238998T1 (de) Substituierte benzimidazole als nicht-nucleoside reverse transcriptase inhibitore
BR9608265A (pt) Compostos de alquiléter e pirimidina-tioalquila alfa-substituídos
ATE93138T1 (de) Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
DK524788A (da) Anvendelse af morphin-antagonister til fremstilling af laegemidler med immunomodulerende og antiviral effekt, isaer til behandling af erhvervede immundefekt-tilstande
DE69019533D1 (de) Behandlung von hiv-infizierungen und nützliche verbindungen dafür.
BR9709838A (pt) Regime de administração que fornece um perfil de plasma no sangue de um inibidor de h+,k+-atpase composição farmacêutica oral uso da mesma e de inibidor h+,k+-atpase e processos para melhorar a inibição de secreção de ácido gástrico e o efeito terapêutico no tratamento de perturbações gastrintestinais e para receber um perfil estendido de plasma de um inibidor de h+,k+-atpase
DK261490D0 (da) New pharmaceutical compound
DK0763017T3 (da) N-(3-amino-2-hydroxybutyl)sulfonamidderivater som HIV-proteaseinhibitorer
KR910700045A (ko) Hiv 감염 관련 질병의 치료
DE69414708D1 (de) Verbindungen und methoden zur inhibition von hiv und verwandten viren
NO951608L (no) Anvendelse av BHAP-forbindelser i kombinasjon med andre ikke-nukleoside reverstranskriptaseinhibitorer for behandling av HIV-infeksjon
BR0317095A (pt) Uso de uma combinação contendo um inibidor da transcriptase reversa sem ser de nucleosìdeo (nnrti) com um inibidor citocromo p450, tal como inibidores da protease
Kasbekar Studies of resting isolated frog gastric mucosa.
DE69909747D1 (de) Pharmazeutische zusammensetzung, enthaltend peg-asparaginase, für die behandlung von hiv infektionen
DK0859613T3 (da) Anvendelse af flupirtin til forebyggelse og behandling af sygdomme, som er forbundet med beskadigelse af det hæmopoietiske cellesystem
HUP9800810A2 (hu) Kombinációs terápia emberi immunhiány-vírusos (HIV) ferőzés kezelésére
KR950702838A (ko) 인터루킨-4(IL-4)를 사용한 사람 면역결핍 바이러스(HIV) 복제의 억제방법(Method for inhibiting HIV replication using IL-4)
WO1997026880A3 (en) Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients
NO965591L (no) Kombinasjonsbehandling av HIV-infeksjon
DK1143976T3 (da) Beta-D-2', 3'-didehydro-2', 3'-dideoxy-5-fluorcytidin til anvendelse i behandlingen af HIV-infektioner
RU94032792A (ru) Применение 5нтiа - антагонистов для прекращения использования табака
DK0910405T3 (da) Vaccine, som indeholder caprint arthritis-encephalitis-virus, og anvendelse til immunbeskyttelse imod HIV-1-infektion
UA31078A (uk) Інгібітор вірусу імунодефіциту людини ( даримід )
NO931338L (no) Forbindelser og fremgangsmaater for inhibering av hiv og beslektede virus